Tenet Healthcare: I Am Caring A Lot More At Current Levels

Tenet Healthcare is trading at just 10x adjusted earnings after a 30% pullback from recent highs, which makes valuation look compelling. 2025 adjusted EPS reached $17, above prior guidance, and 2026 outlook calls for continued earnings stability plus robust buybacks. Revenue growth is being driven by higher pricing despite flat volumes and some margin pressure, but the business remains broadly stable.

Analysis

THC screens as a classic quality-compounding setup rather than a pure value trap: the market is still discounting cyclical deterioration even as earnings power is proving more durable than feared. The key second-order effect is that stability in a high-fixed-cost hospital model can drive disproportionately strong equity returns when buybacks remain aggressive — modest earnings resilience can translate into outsized per-share growth once share count starts shrinking faster than operating income.

The competitive read-through is more interesting than the headline valuation. If pricing is doing the heavy lifting while volumes stay flat, the signal is that acute-care demand is not being materially displaced, but there is limited room for rivals to outgrow through utilization alone; that tends to favor the larger operators with better payer mix and stronger balance sheets. It also means labor or reimbursement pressure can still compress margins, so the “winner” is not the operator with the best top-line growth, but the one with the best capital allocation and highest buyback capacity.

The main risk is that the market is currently rewarding the stability story before it fully tests the next leg of reimbursement and labor costs over the next 2-4 quarters. If pricing normalizes or payers push back, the multiple can de-rate quickly because the stock is being valued as if earnings are low-volatility. In contrast, if 2026 guidance merely confirms flat-to-slightly-up EPS plus ongoing repurchases, the setup can re-rate without much help from revenue growth.

Consensus may be underestimating how much of THC’s upside can come from per-share math rather than operating acceleration. A 30% drawdown has already done most of the work on sentiment, so the asymmetry now is less about a sharp fundamental inflection and more about the market closing the gap between a mid-teens-quality earnings stream and a 10x multiple. That makes this more compelling on confirmation than on anticipation.

Key Decisions for Investors

• Go long THC over 3-6 months on any post-earnings pullback; target a re-rating from ~10x toward 12-13x if 2026 guidance holds, with downside limited if buybacks continue at the current pace.
• Pair trade: long THC / short a weaker hospital operator with higher leverage and less repurchase capacity for 2-4 quarters; the trade is designed to isolate capital return and balance-sheet quality from sector beta.
• Use call spreads rather than outright stock if entering before the next guidance update: buy THC 6-9 month call spreads to capture a multiple recovery while capping risk if payer pushback or labor costs surprise.
• If the stock rallies back toward prior highs before a second confirmation of pricing durability, trim 25-50% of the position; the market will likely front-run stability, but the re-rating needs continued buyback execution to sustain.